

MEDIA RELEASE

16 May 2023

Final Director's Interest Notice – Dr Gillies O'Bryan-Tear

Clarity Pharmaceuticals (ASX: CU6) ("Clarity", "the Company"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, attaches here the *Appendix 3Z Final Director's Interest Notice* for Dr Gillies O'Bryan-Tear. As reported to the market on 1st February with the appointment of Ms. Cheryl Maley to the Clarity Board, Dr O'Bryan Tear stepped down from the Clarity Board with an effective date of 15th May 2023. We wish Dr O'Bryan-Tear all the best with his future endeavours.

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.

www.claritypharmaceuticals.com

For more information, please contact:**Clarity Pharmaceuticals**

Dr Alan Taylor

Executive Chairmanataylor@claritypharm.com

Catherine Strong

Investor/Media Relationscstrong@citadelmagnus.com

+61 406 759 268

This announcement has been authorised for release by the Executive Chairman.

Appendix 3Z

Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Clarity Pharmaceuticals Ltd
ABN	36 143 005 341

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Charles Gillies O'Bryan-Tear
Date of last notice	23 June 2022
Date that director ceased to be director	15 May 2023

Part 1 – Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities <ul style="list-style-type: none">• 300,000 options exercisable at \$0.605 each on or before 21 March 2024• 150,000 options exercisable at \$0.825 each on or before 18 December 2024• 400,000 options exercisable at \$0.938 each on or before 2 March 2025• 120,000 ordinary shares
--

+ See chapter 19 for defined terms.

Appendix 3Z

Final Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest	Number & class of securities
Note: Provide details of the circumstances giving rise to the relevant interest	
Nil	

Part 3 – Director's interests in contracts

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
No. and class of securities to which interest relates	n/a

+ See chapter 19 for defined terms.